361550-43-8

Basic information

• Product Name: (5-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (5-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER;TERT-BUTYL 5-BROMOPYRIDIN-3-YLCARBAMATE;Zinc04352716;tert-Butyl N-(5-broMopyridin-3-yl)carbaMate;3-(Boc-amino)-5-bromopyridine;5-(Boc-amino)-3-bromopyridine;tert-Butyl 5-bromopyridine-3-carbamate;5-Bromo-3-(Boc-amino)-pyridine
• CAS NO: 361550-43-8
• Molecular Formula: C₁₀H₁₃BrN₂O₂
• Molecular Weight: 273.13
• Mol File: 361550-43-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 143-148°C
• Boiling Point: 286.5 °C at 760 mmHg
• Flash Point: 127.1 °C
• Appearance: /
• Density: 1.453 g/cm³
• Vapor Pressure: 0.00262mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (5-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (5-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER(361550-43-8)
• EPA Substance Registry System: (5-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER(361550-43-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 361550-43-8(Hazardous Substances Data)

Usage

General Description

(5-Bromo-pyridin-3-yl)-carbamic acid tert-butyl ester is a chemical compound that consists of a pyridine ring with a bromine substituent at the 5th position and a carbamic acid tert-butyl ester functional group. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. (5-BROMO-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER is known for its role in the development of new drug candidates due to its ability to modify biological targets. Additionally, it has been studied for its potential use as a pesticide and herbicide. Its unique structure and properties make it a valuable tool in the field of medicinal and agricultural chemistry.

InChI:InChI=1/C10H13BrN2O2/c1-10(2,3)15-9(14)13-8-4-7(11)5-12-6-8/h4-6H,1-3H3,(H,13,14)

Upstream product

• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 626-55-1 3-Bromopyridine 
• 625-92-3 3,5-dibromopyridine 
• 4248-19-5 tert-butyl carbazate 
• 13535-01-8 3-amino-5-bromopyridine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 857266-59-2 tert-butyl (5-iodopyridin-3-yl)carbamate 
• 2079886-19-2 GSK4027 
• 2079886-19-2 GSK4028 
• 2079886-19-2 4-bromo-2-methyl-5-(((3RS,5RS)-1-methyl-5-phenylpiperidin-3-yl)amino)pyridazin-3(2H)-one 
• 1171897-39-4 tert-butyl (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)carbamate 

Relevant articles and documents

A multifunctional reagent designed for the site-selective amination of pyridines

We report the development of a multifunctional reagent for the direct conversion of pyridines to Boc-protected 2-aminopyridines with exquisite site selectivity and chemoselectivity. The novel reagent was prepared on 200-g scale in a single step, reacts in the title reaction under mild conditions without precautions toward air or moisture, and is tolerant of nearly all common functionality. Experimental and in situ spectroscopic monitoring techniques provide detailed insights and unexpected findings for the unique reaction mechanism.

Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

We have recently disclosed 5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine 1 as a potent IKur current blocker with selectivity versus hERG, Na and Ca channels, and an acceptable preclinical PK profile. Upon further characterization in vivo, compound 1 demonstrated an unacceptable level of brain penetration. In an effort to reduce the level of brain penetration while maintaining the overall profile, SAR was developed at the C2′ position for a series of close analogues by employing hydrogen bond donors. As a result, 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide (25) was identified as the lead compound in this series. Compound 25 showed robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species pharmacokinetic profile and was advanced as the clinical candidate. Further optimization of 25 to mitigate pH-dependent absorption resulted in identification of the corresponding phosphoramide prodrug (29) with an improved solubility and pharmacokinetic profile.

Pleuromutilin derivatives such, its pharmaceutical composition and synthetic method and use thereof

The present invention relates to a class of pleuromytilin compounds represented by the following general formula (I), pharmaceutically acceptable salts and preparation methods thereof, and compositions comprising the compound represented by the general fo